Volume 14, Issue 3 (9-2026)                   JoMMID 2026, 14(3): 191-199 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kazemi R, Hamidi-Fard M, Siasi E, Aghasadeghi M R, Rahimi P. Temporal Changes in Long Non-Coding RNA HULC Expression in Hepatitis B Virus-Associated Hepatocellular Carcinoma Cells Infected with Oncolytic Reovirus: An In Vitro Study. JoMMID 2026; 14 (3) :191-199
URL: http://jommid.pasteur.ac.ir/article-1-842-en.html
Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran
Abstract:   (13 Views)
Introduction: HULC is a long non-coding RNA (lncRNA) implicated in hepatocellular carcinoma (HCC), including hepatitis B virus (HBV)-associated disease. Mammalian orthoreovirus (reovirus) exhibits oncolytic activity in experimental cancer models. This study examined temporal changes in HULC expression and intracellular reovirus RNA in patient-derived HBV-associated HCC cells and Huh-7 cells following infection. Methods: Both cell models were exposed to reovirus at a multiplicity of infection of 10. Cells were collected at 0, 24, 48, and 72 hours post-infection (hpi). HULC expression and reovirus L1 RNA were assessed by reverse-transcription quantitative PCR (RT-qPCR); cell metabolic activity and viability were examined using MTT and trypan blue assays, respectively. Results: Reovirus L1 threshold-cycle values decreased over time in both cell models, consistent with increasing intracellular viral RNA abundance, with the lowest values at 72 hpi. Relative HULC expression increased at 24 and 48 hpi and decreased below the 0-hpi reference at 72 hpi. At 24 and 48 hpi, HULC fold changes were greater in the patient-derived cells than in Huh-7 cells; this relationship was reversed at 72 hpi. Both cell types showed reduced metabolic activity and viability during infection. Conclusion: Reovirus exposure was associated with a transient increase in HULC expression followed by reduced expression at 72 hpi. These descriptive findings do not establish that HULC regulates viral replication or that the effect is HBV-specific. Confirmation using additional biological replicates, time-matched uninfected controls, and infectious-virus assays is required.
Full-Text [PDF 1089 kb]   (4 Downloads)    
Type of Study: Original article | Subject: Other
Received: 2026/06/5 | Accepted: 2026/09/10 | Published: 2026/11/16

References
1. Mauro E, de Castro T, Zeitlhoefler M, Sung MW, Villanueva A, Mazzaferro V, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7(12):101571. [DOI:10.1016/j.jhepr.2025.101571] [PMID] [PMCID]
2. Méndez-Sánchez N, Valencia-Rodríguez A, Coronel-Castillo CE, Qi X. Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Dig Med Res. 2021;4:15. [DOI:10.21037/dmr-20-116]
3. Ma L, Chen S, Wang H, Chen L. Hepatitis B virus integration and hepatocarcinogenesis. Liver Res. 2025;9(3):189-98. [DOI:10.1016/j.livres.2025.09.002] [PMID] [PMCID]
4. Liang W, Zhao Y, Meng Q, Jiang W, Deng S, Xue J. The role of long non-coding RNA in hepatocellular carcinoma. Aging (Albany NY). 2024;16(4):4052-73. [DOI:10.18632/aging.205523] [PMID] [PMCID]
5. Zhang H, Liao Z, Liu F, Su C, Zhu H, Li Y, et al. Long noncoding RNA HULC promotes hepatocellular carcinoma progression. Aging (Albany NY). 2019;11(20):9111-27. [DOI:10.18632/aging.102378] [PMID] [PMCID]
6. Xin X, Wu M, Meng Q, Wang C, Lu Y, Yang Y, et al. Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a. Mol Cancer. 2018;17(1):94. [DOI:10.1186/s12943-018-0843-8] [PMID] [PMCID]
7. Qiu L, Wang T, Xu X, Wu Y, Tang Q, Chen K. Long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma: regulation, functions, and underlying mechanisms. Int J Mol Sci. 2017;18(12):2505. [DOI:10.3390/ijms18122505] [PMID] [PMCID]
8. Elzein SM, Brombosz EW, Kodali S. Liver transplantation for cancer-current challenges and emerging solutions. J Clin Med. 2025;14(15):5365. [DOI:10.3390/jcm14155365] [PMID] [PMCID]
9. Yousef EH, El Gayar AM, El-Magd NFA. Insights into sorafenib resistance in hepatocellular carcinoma: mechanisms and therapeutic aspects. Crit Rev Oncol Hematol. 2025;212:104765. [DOI:10.1016/j.critrevonc.2025.104765] [PMID]
10. Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic virus-based immunotherapies for hepatocellular carcinoma. Mediators Inflamm. 2017;2017:5198798. [DOI:10.1155/2017/5198798] [PMID] [PMCID]
11. Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: the key to breaking the log jam? Cancer Med. 2020;9(9):2943-59. [DOI:10.1002/cam4.2949] [PMID] [PMCID]
12. Moon H, Ro SW. MAPK/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13(12):3026. [DOI:10.3390/cancers13123026] [PMID] [PMCID]
13. Kazemi R, Ataei-Pirkooh A, Aghasadeghi MR, Modaresi MH, Hamidi-Fard M. Human reovirus serotype 3 effectively targets Huh-7 cells. Iran J Virol. 2020;14(2):23-8.
14. Kazemi R, Ataei-Pirkooh A, Aghasadeghi MR, Etemadzadeh MH, Alavian SM, Ghanaati H, et al. The effects of human reoviruses on cancer cells derived from hepatocellular carcinoma biopsies. Clin Lab. 2021;67(3):681-7. [DOI:10.7754/Clin.Lab.2020.200416] [PMID]
15. Fu LY, Jia HL, Dong QZ, Wu JC, Zhao Y, Zhou HJ, et al. Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses. BMC Cancer. 2009;9:49. [DOI:10.1186/1471-2407-9-49] [PMID] [PMCID]
16. Gao Q, Wang XY, Fan J, Qiu SJ, Zhou J, Shi YH, et al. Selection of reference genes for real-time PCR in human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol. 2008;134(9):979-86. [DOI:10.1007/s00432-008-0369-3] [PMID] [PMCID]
17. Tyler KL, Sokol RJ, Oberhaus SM, Le M, Karrer FM, Narkewicz MR, et al. Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Hepatology. 1998;27(6):1475-82. [DOI:10.1002/hep.510270603] [PMID]
18. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313(4):856-62. [DOI:10.1016/j.bbrc.2003.11.177] [PMID]
19. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330-42. [DOI:10.1053/j.gastro.2006.08.026] [PMID]
20. Rodríguez Stewart RM, Berry JT, Berger AK, Yoon SB, Hirsch AL, Guberman JA, et al. Enhanced killing of triple-negative breast cancer cells by reassortant reovirus and topoisomerase inhibitors. J Virol. 2019;93(23):e01411-19. [DOI:10.1128/JVI.01411-19] [PMID] [PMCID]
21. Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers (Basel). 2020;12(11):3219. [DOI:10.3390/cancers12113219] [PMID] [PMCID]
22. Berry JT, Muñoz LE, Stewart RMR, Selvaraj P, Mainou BA. Doxorubicin conjugation to reovirus improves oncolytic efficacy in triple-negative breast cancer. Mol Ther Oncolytics. 2020;18:556-72. [DOI:10.1016/j.omto.2020.08.008] [PMID] [PMCID]
23. Jiffry J, Thavornwatanayong T, Rao D, Fogel EJ, Saytoo D, Nahata R, et al. Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer. Clin Cancer Res. 2021;27(3):865-76. [DOI:10.1158/1078-0432.CCR-20-2385] [PMID] [PMCID]
24. Pérez-Domínguez F, Quezada-Monrás C, Cárcamo L, Muñoz JP, Carrillo-Beltrán D. Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions. Cancers (Basel). 2025;17(11):1854. [DOI:10.3390/cancers17111854] [PMID] [PMCID]
25. Rastegarpanah M, Kafi ZZ, Negahdari B. In vivo tracking modalities for oncolytic reovirus: principles, clinical applications, and translational integration. Mol Imaging Biol. 2026;28(3):400-16. [DOI:10.1007/s11307-026-02092-x] [PMID]
26. Kitabayashi J, Shirasaki T, Shimakami T, Nishiyama T, Welsch C, Funaki M, et al. Upregulation of the long noncoding RNA HULC by hepatitis C virus and its regulation of viral replication. J Infect Dis. 2022;226(3):407-19. [DOI:10.1093/infdis/jiaa325] [PMID] [PMCID]
27. Sharma G, Tripathi SK, Das S. lncRNA HULC facilitates efficient loading of HCV-core protein onto lipid droplets and subsequent virus-particle release. Cell Microbiol. 2019;21(10):e13086. [DOI:10.1111/cmi.13086]
28. Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158-70. [DOI:10.1016/j.canlet.2019.04.008] [PMID]
29. Meng XY, Luo Y, Anwar MN, Sun Y, Gao Y, Zhang H, et al. Long non-coding RNAs: emerging and versatile regulators in host-virus interactions. Front Immunol. 2017;8:1663. [DOI:10.3389/fimmu.2017.01663] [PMID] [PMCID]
30. Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2018;67(3):562-73. [DOI:10.1136/gutjnl-2016-312009] [PMID] [PMCID]
31. Samudh N, Shrilall C, Arbuthnot P, Bloom K, Ely A. Diversity of dysregulated long non-coding RNAs in HBV-related hepatocellular carcinoma. Front Immunol. 2022;13:834650. [DOI:10.3389/fimmu.2022.834650] [PMID] [PMCID]
32. Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. Cells. 2022;11(4):741. [DOI:10.3390/cells11040741] [PMID] [PMCID]
33. Husein A, Jamal A, Kamal MA, Alqurashi YE, Al-Malki ES, Naiyer MM, et al. Hepatitis B virus-induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities. Cancer Gene Ther. 2026;33:612-23. [DOI:10.1038/s41417-026-01051-6] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.